Clinical Trial Update: An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies [Phase 1]

View source ↗

Summary

Hoffmann-La Roche announced completion of an extension study for RO5045337 in participants from previous Roche cancer studies, involving chronic and acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• RO5045337 (RO5045337)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute | Phase 1 | Status: COMPLETED